InspireMD

OverviewSuggest Edit

InspireMD was founded in 2005 with the purpose of creating a technology that could solve the problem of embolization in high risk vascular procedures. The company has grown to include a portfolio of embolic protection systems, which it both manufactures and commercializes.
Today, InspireMD is a global company headquartered in Boston, MA. InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection by providing a superior solution to the key clinical issues of vascular procedures.

TypePublic
Founded2005
HQTel Aviv-Yafo, ILMap
Websiteinspiremd.com

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2019)43(+20%)
Revenue (FY, 2019)$3.7 M(+4%)
Share Price (Nov 2020)$0.4 (+3%)
Cybersecurity ratingCMore

Key People/Management at InspireMD

Marvin Slosman

Marvin Slosman

Chief Executive Officer & Director
Paul Stuka

Paul Stuka

Chairman of the Board
Craig Shore

Craig Shore

Chief Financial Officer
Michael Berman

Michael Berman

Director
Show more

InspireMD Office Locations

InspireMD has offices in Tel Aviv-Yafo and Winsen (Luhe)
Tel Aviv-Yafo, IL (HQ)
4 Menorat HaMa'or St
Winsen (Luhe), DE
16 Boschstraße
Show all (2)

InspireMD Financials and Metrics

InspireMD Revenue

Embed Graph
View revenue for all periods
InspireMD's revenue was reported to be $3.72 m in FY, 2019
USD

Revenue (Q2, 2020)

313.0k

Gross profit (Q2, 2020)

(120.0k)

Gross profit margin (Q2, 2020), %

(38.3%)

Net income (Q2, 2020)

(2.5m)

EBIT (Q2, 2020)

(2.4m)

Market capitalization (18-Nov-2020)

13.3m

Closing stock price (18-Nov-2020)

0.4

Cash (30-Jun-2020)

13.9m

EV

(81.3k)
InspireMD's current market capitalization is $13.3 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

6.0m2.1m3.1m2.8m2.3m1.9m2.8m3.6m3.7m

Revenue growth, %

(26%)(18%)

Cost of goods sold

3.0m1.4m1.4m2.0m2.6m1.8m2.2m2.6m3.0m

Gross profit

3.0m694.0k1.7m784.0k(296.0k)102.0k585.0k995.0k756.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2013Q3, 2013Q1, 2014Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.0m2.0m1.1m1.4m1.5m1.6m1.5m193.0k273.0k477.0k685.0k632.0k563.0k540.0k469.0k569.0k640.0k718.0k1.0m1.0m769.0k415.0k1.4m939.0k1.0m313.0k

Cost of goods sold

640.0k801.0k574.0k547.0k674.0k750.0k625.0k584.0k349.0k514.0k897.0k543.0k497.0k478.0k438.0k495.0k493.0k565.0k714.0k726.0k571.0k488.0k912.0k811.0k739.0k433.0k

Gross profit

400.0k1.2m564.0k803.0k840.0k802.0k857.0k(391.0k)(76.0k)(37.0k)(212.0k)89.0k66.0k62.0k31.0k74.0k147.0k153.0k293.0k277.0k198.0k(73.0k)442.0k128.0k295.0k(120.0k)

Gross profit Margin, %

38%60%50%59%55%52%58%(203%)(28%)(8%)(31%)14%12%11%7%13%23%21%29%28%26%(18%)33%14%29%(38%)
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.1m10.3m17.5m3.3m7.5m3.7m9.4m5.5m

Accounts Receivable

2.3m1.8m1.9m405.0k643.0k716.0k823.0k

Prepaid Expenses

72.0k93.0k141.0k75.0k62.0k81.0k87.0k

Inventories

2.1m1.7m1.6m753.0k500.0k533.0k1.1m1.2m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2013Q3, 2013Q1, 2014Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

8.1m7.5m3.4m5.4m2.5m11.4m13.7m9.0m5.0m13.2m9.8m6.5m2.0m885.0k10.5m8.6m6.9m4.8m4.6m6.4m11.2m5.8m4.8m7.2m3.1m13.9m

Accounts Receivable

614.0k1.8m2.0m1.3m2.1m2.1m1.5m493.0k397.0k719.0k728.0k546.0k432.0k542.0k471.0k451.0k538.0k754.0k916.0k710.0k464.0k861.0k796.0k856.0k416.0k

Prepaid Expenses

71.0k103.0k89.0k94.0k91.0k144.0k110.0k215.0k138.0k109.0k76.0k62.0k41.0k107.0k21.0k73.0k109.0k53.0k71.0k145.0k66.0k44.0k155.0k63.0k40.0k

Inventories

1.5m1.9m2.0m2.0m2.0m1.4m1.3m1.5m1.7m1.8m1.2m1.1m511.0k387.0k365.0k329.0k429.0k576.0k517.0k637.0k816.0k1.4m1.2m1.3m1.2m1.4m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(14.7m)(7.1m)(9.3m)(25.1m)(15.6m)(8.5m)(8.4m)(7.2m)(10.0m)

Depreciation and Amortization

89.0k69.0k188.0k263.0k241.0k191.0k178.0k152.0k158.0k

Inventories

(261.0k)317.0k(331.0k)1.2m253.0k(33.0k)(601.0k)(102.0k)

Accounts Payable

(371.0k)(291.0k)737.0k(659.0k)(397.0k)106.0k(290.0k)584.0k(283.0k)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2013Q3, 2013Q1, 2014Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(4.1m)(6.4m)(3.1m)(9.4m)(14.3m)(3.9m)(6.0m)(13.5m)(20.3m)(5.2m)(9.1m)(12.7m)(2.6m)(4.6m)(6.6m)(2.6m)(4.9m)(6.9m)(2.4m)(3.0m)(5.0m)(3.2m)(5.4m)(7.5m)(2.0m)(4.5m)

Depreciation and Amortization

38.0k52.0k34.0k95.0k146.0k50.0k56.0k122.0k181.0k75.0k135.0k195.0k48.0k95.0k143.0k42.0k84.0k127.0k41.0k79.0k115.0k35.0k73.0k114.0k51.0k88.0k

Inventories

(51.0k)(233.0k)(238.0k)201.0k250.0k79.0k(89.0k)174.0k695.0k843.0k242.0k366.0k388.0k171.0k71.0k(76.0k)16.0k(104.0k)(283.0k)(313.0k)(84.0k)(149.0k)34.0k(166.0k)

Accounts Payable

(340.0k)(541.0k)(481.0k)60.0k(65.0k)19.0k(218.0k)(94.0k)(75.0k)(244.0k)(418.0k)(75.0k)(59.0k)686.0k(103.0k)(267.0k)(145.0k)(216.0k)184.0k148.0k128.0k(57.0k)(311.0k)(242.0k)(84.0k)(188.0k)
show all
USDQ2, 2011

Financial Leverage

1.6 x
Show all financial metrics

InspireMD Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

Learn more about our premium products
SecurityScorecard logo

InspireMD Online and Social Media Presence

InspireMD's Trends

Embed Graph

InspireMD News and Updates

November 09, 2020

InspireMD Announces Third Quarter 2020 Financial Results

Third quarter 2020 revenue returns to pre-COVID-19 levels
October 13, 2020

InspireMD Announces Renowned Interventional Cardiologist Gary S. Roubin, M.D., Ph.D., to Join Board of Directors

TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the addition of Gary Roubin, M.D., Ph.D., to InspireMD’s Boar…
October 06, 2020

InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide §711(a)

TEL AVIV, Israel, Oct. 06, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the appointment of Patrick Jamnik as vice preside…
September 10, 2020

InspireMD Announces Christina Brennan, M.D., MBA to Serve in Advisory Role for Pivotal Study of CGuard Carotid Stent System

Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States
September 03, 2020

InspireMD Announces the European Society of Cardiology 2020 “Best Poster Award” for Updated Data from the PARADIGM-EXTEND Study

TEL AVIV, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the award for Best ESC Congress Poster for the presentation …
August 25, 2020

InspireMD to Present at the LD Micro 500 Virtual Conference on September 3, 2020

TEL AVIV, Israel, Aug. 25, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that Marvin Slosman, President and Chief Executive Off…
Show more

 InspireMD Frequently Asked Questions

  • When was InspireMD founded?

    InspireMD was founded in 2005.

  • Who are InspireMD key executives?

    InspireMD's key executives are Marvin Slosman, Paul Stuka and Craig Shore.

  • How many employees does InspireMD have?

    InspireMD has 43 employees.

  • What is InspireMD revenue?

    Latest InspireMD annual revenue is $3.7 m.

  • What is InspireMD revenue per employee?

    Latest InspireMD revenue per employee is $86.5 k.

  • Who are InspireMD competitors?

    Competitors of InspireMD include Elanix Biotechnologies, 19Labs and Biovotion.

  • Where is InspireMD headquarters?

    InspireMD headquarters is located at 4 Menorat HaMa'or St, Tel Aviv-Yafo.

  • Where are InspireMD offices?

    InspireMD has offices in Tel Aviv-Yafo and Winsen (Luhe).

  • How many offices does InspireMD have?

    InspireMD has 2 offices.